So basically they want to make a go elsewhere, but at the same time want American style protections? Basically to go over the heads of their host countries governments and tell them what to do?
Actually they want to do development in other countries to gain access to their NHS programs (The purchaser of their product) and then submit that research to our NHS. This works for large Pharma companies that have a global scope but not for small startups that tend to be the most innovative. For them the cost of development is so expensive as to be a barrier to entry. As with all NHS systems it is good for the big companies as it limits competition from the small companies.